Your browser doesn't support javascript.
loading
The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma
Hospital de Clínicas de Porto AlegreScheffel, Rafael Selbach; Hospital de Clínicas de Porto AlegreCristo, Ana Patrícia de; Romitti, Mirian; Hospital de Clínicas de Porto AlegreVargas, Carla Vaz Ferreira; Hospital de Clínicas de Porto AlegreCeolin, Lucieli; Hospital de Clínicas de Porto AlegreZanella, André B.; Hospital de Clínicas de Porto AlegreDora, Jose Miguel; Hospital de Clínicas de Porto AlegreMaia, Ana Luiza.
Afiliación
  • Hospital de Clínicas de Porto AlegreScheffel, Rafael Selbach; Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Hospital de Clínicas de Porto AlegreScheffel, Rafael Selbach. Porto Alegre. BR
  • Hospital de Clínicas de Porto AlegreCristo, Ana Patrícia de; Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Hospital de Clínicas de Porto AlegreCristo, Ana Patrícia de. Porto Alegre. BR
  • Romitti, Mirian; Université Libre de Bruxelles. Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire. Brussels. BE
  • Hospital de Clínicas de Porto AlegreVargas, Carla Vaz Ferreira; Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Hospital de Clínicas de Porto AlegreVargas, Carla Vaz Ferreira. Porto Alegre. BR
  • Hospital de Clínicas de Porto AlegreCeolin, Lucieli; Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Hospital de Clínicas de Porto AlegreCeolin, Lucieli. Porto Alegre. BR
  • Hospital de Clínicas de Porto AlegreZanella, André B.; Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Hospital de Clínicas de Porto AlegreZanella, André B.. Porto Alegre. BR
  • Hospital de Clínicas de Porto AlegreDora, Jose Miguel; Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Hospital de Clínicas de Porto AlegreDora, Jose Miguel. Porto Alegre. BR
  • Hospital de Clínicas de Porto AlegreMaia, Ana Luiza; Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Hospital de Clínicas de Porto AlegreMaia, Ana Luiza. Porto Alegre. BR
Arch. endocrinol. metab. (Online) ; 64(6): 751-757, Nov.-Dec. 2020. tab
Article en En | LILACS | ID: biblio-1142196
Biblioteca responsable: BR1.1
ABSTRACT
ABSTRACT

Objective:

Although the prognostic role of BRAFV600E mutation in papillary thyroid carcinoma (PTC) is controversial, the American Thyroid Association (ATA) includes the mutational status in their risk stratification system. To evaluate the impact of the BRAFV600E mutation status on PTC risk stratification. Subjects and

methods:

PTC patients attending a university-based hospital who had the analysis of the BRAFV600E mutation were included. Persistent disease was defined as the presence of biochemical or structural disease. The performance of the ATA risk stratification system on predicting persistent disease with or without the BRAFV600E mutation status information was evaluated.

Results:

Of the 134 patients evaluated, 44 (32.8%) carried BRAFV600E mutation. The median tumor size was 1.7 cm (P25-75 1.0-3.0), 64 (47.8%) patients had lymph node, and 11 (8.2%) distant metastases. According to the ATA risk stratification system, patients were classified as low, intermediate, and high risk in 55 (41%), 59 (44%), and 20 (14%) patients, respectively. The data on BRAFV600E mutation reclassified 12 (8.9%) patients from low to intermediate risk. After a median follow-up of 8.5 years, the prevalence of persistent disease was similar in patients with and without BRAFV600E mutation (P = 0.42). Multivariate analysis failed to demonstrate an association between the BRAFV600E mutation and persistent disease status (RR 0.96; 95%CI 0.47-1.94). Notably, none of the patients reclassified from low to intermediate risk showed persistent disease on follow-up.

Conclusion:

Inclusion of BRAFV600E mutational status has a limited impact on risk stratification and does not add to the prediction of outcomes in PTC patients.
Asunto(s)
Palabras clave

Texto completo: 1 Índice: LILACS Asunto principal: Neoplasias de la Tiroides / Carcinoma / Carcinoma Papilar Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Arch. endocrinol. metab. (Online) Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2020 Tipo del documento: Article

Texto completo: 1 Índice: LILACS Asunto principal: Neoplasias de la Tiroides / Carcinoma / Carcinoma Papilar Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Arch. endocrinol. metab. (Online) Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2020 Tipo del documento: Article